1 ASX RELEASE 11 September 2026 Cleansing Notice - Issue of Convertible Notes This cleansing notice (“Cleansing Notice”) is given by Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), under section 708A(12C)(e) of the Corporations Act 2001 (Cth)...
Notice under Section 708A
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Notification regarding unquoted securities - PAR
- Drawdown of Tranche 4 under the Convertible Note Facility
- Application for quotation of securities - PAR
- Melbourne Investor Lunch
- Appendix 4E and 2026 Annual Report
Later from Paradigm Biopharmaceuticals
- Dr Daniel Furtner appointed Chief Medical Officer
- Trading Halt
- Suspension from Quotation
- Phase 3 Interim Result Below Continuation Threshold
- Notification of cessation of securities - PAR
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals